In Brief: Endo Buys Somar; Neptune, Enzymotec Settle Dispute; FDA Prohibits Omega-3 Nutrient Claims
This article was originally published in The Tan Sheet
Endo buys Somar; Neptune, Enzymotec settle patent infringement; FDA prohibits omega-3 nutrient claims; “Sell through” for herbals ends in U.K.; C&D licenses Nutrition 21’s chromium picolinate; Arizona DXM bill and Iowa Select Herbs drug claims.
You may also be interested in...
The settlement terms are confidential, but Pfizer “acknowledged the validity of Nutrition 21’s asserted patents” and the Centrum line “may continue to use chromium picolinate,” Nutrition 21 says. The firms agreed as attorneys prepared to begin questioning a pool of potential jurors for the trial.
In recent interview, CEO Blake Cadwell talked about Soundly’s business model and outlook for hearing aid marketplace after FDA's pending publication of rule aiming to make the devices more accessible. Firm since June has offered online testing and advice for customers about hearing aids best suited for their needs.
Revlon approved for $1.4bn debtor-in-possession financing from BrandCo Lenders, a group of operating subsidiaries formed in capital structure changes which owns much of Revlon’s intellectual property. Firm appoints interim CFO to set course for debt restructuring.